Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI)
- Previous Close
2.1900 - Open
2.2100 - Bid 2.2000 x --
- Ask 2.2100 x --
- Day's Range
2.2100 - 2.2200 - 52 Week Range
1.9900 - 2.6600 - Volume
49,500 - Avg. Volume
140,767 - Market Cap (intraday)
2.812B - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
5.53 - EPS (TTM)
0.4000 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield 0.18 (8.20%)
- Ex-Dividend Date Jul 2, 2024
- 1y Target Est
--
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao Jiuxin pills, Qingyan drop pills, Jingwanhong ointment, Angong Niuhuang pills, Qingfei pills, anti-inflammatory pills, Qinggong Shoutao pills, Biqi capsules, Niuhuang Qingxin pills, Tongmai Yangxin pills, and Weichang An pills. Additionally, the company pharmaceutical logistic services. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1981 and is based in Tianjin, the People's Republic of China.
www.jydrt.com.cn--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: T14.SI
View MorePerformance Overview: T14.SI
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: T14.SI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: T14.SI
View MoreValuation Measures
Market Cap
2.80B
Enterprise Value
2.61B
Trailing P/E
5.49
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.82
Price/Book (mrq)
1.48
Enterprise Value/Revenue
2.82
Enterprise Value/EBITDA
7.20
Financial Highlights
Profitability and Income Statement
Profit Margin
30.51%
Return on Assets (ttm)
4.79%
Return on Equity (ttm)
30.56%
Revenue (ttm)
7.31B
Net Income Avi to Common (ttm)
2.23B
Diluted EPS (ttm)
0.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.94B
Total Debt/Equity (mrq)
0.36%
Levered Free Cash Flow (ttm)
1.84B